Get startedLog in
    Picture of Venmax Drugs and Pharmaceuticals logo

    531015 — Venmax Drugs and Pharmaceuticals Income Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Venmax Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1.680008.07
    Cost of Revenue
    Gross Profit-1.260000.127
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Other Operating Expenses
    Total Operating Expenses5.111.361.941.1218.7
    Operating Profit-3.43-1.36-1.94-1.12-10.7
    Other Net Non Operating Costs
    Net Income Before Taxes-1.6218.52.260.869-0.141
    Provision for Income Taxes
    Net Income After Taxes-1.6218.52.260.645-0.105
    Net Income Before Extraordinary Items
    Net Income-1.6218.52.260.645-0.105
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-1.6218.52.260.645-0.105
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.313.520.430.12-0.02